Tags | Domains | Searches | Statistics | Options | Advanced Search
|
Tags | Domains | Searches | Statistics | Options | Advanced Search |
In the Pipeline - Jul 31, 2008
Today we take up the extremely interesting story of Rember, hailed in this week’s press as a potential wonder drug for Alzheimer’s. There are a lot of unusual features to this one. To take the most obvious first, the …
In the Pipeline - Jul 30, 2008
Elan and Wyeth unveiled the data on their widely anticipated Alzheimer’s drug bapineuzumab yesterday. This is another antibody from Elan’s shop, part of a long-running effort to induce an immune response to the amyloid …
In the Pipeline - Jun 30, 2008
I was mentioning the gamma secretase enzyme around here just the other day as a longstanding target for Alzheimer's therapy. I remember the periodduring the 1990s when the enzyme hadn't been identified yet, and …
In the Pipeline - Jun 17, 2008
Let’s start from first principles: most drugs mess something up. More elegantly, most drugs inhibit some enzyme’s activity or block some receptor’s binding site. Proteins are generally pretty well optimized at what …
In the Pipeline - Jun 13, 2008
The long-running saga of Elan's attempt to come up with a vaccine for Alzheimer's disease continues. There have been bold attempts, setbacks, rethinks, more setbacks, and now they're starting up again. Dosing of the …
In the Pipeline - May 7, 2008
Several recent papers in Neurology offer some interesting ideas on Alzheimer's disease. The one that's getting some headlines today suggests that long-term use of ibuprofen has a protective effect against the disease …
In the Pipeline - Feb 28, 2008
Science has coverage of a diagnostic test for the APOE gene that’s coming into the market. For about $400, you can find out what form of the protein you have. The problem is, the main thing this test is good for is …
In the Pipeline - Feb 11, 2008
One of the first projects I ever worked on when I started in industry was targeting Alzheimer's disease. Things could have easily worked out to find me still targeting Alzheimer's disease, nearly twenty years later …
In the Pipeline - May 17, 2007
(My apologies for no update today - it's been hectic around here, for reasons that I hope to be able to reveal soon). Some of the first work I did in the industry was on Alzheimer's disease. It's hard stuff to deal …